Skip to main content

Articles

Page 6 of 14

  1. Circular RNAs (circRNAs) are important regulators of the development and progression of non-small-cell lung cancer (NSCLC) and many other malignancies. The functional importance of circ_0009043 in NSCLC, howev...

    Authors: Kelin She, Shaoqi Yu, Shushuai He, Wen Wang and Biao Chen
    Citation: Biomarker Research 2022 10:61
  2. Liver cancer is one of the most common malignant tumors worldwide, it is ranked sixth in incidence and fourth in mortality. According to the distinct origin of malignant tumor cells, liver cancer is mainly div...

    Authors: Hao Peng, Erwei Zhu and Yewei Zhang
    Citation: Biomarker Research 2022 10:59
  3. Circulating tumor cells (CTCs) are cells that shed from a primary tumor and travel through the bloodstream. Studying the functional and molecular characteristics of CTCs may provide in-depth knowledge regardin...

    Authors: Siwei Ju, Cong Chen, Jiahang Zhang, Lin Xu, Xun Zhang, Zhaoqing Li, Yongxia Chen, Jichun Zhou, Feiyang Ji and Linbo Wang
    Citation: Biomarker Research 2022 10:58
  4. Intercellular communication is mediated by extracellular vesicles (EVs), as they enclose selectively packaged biomolecules that can be horizontally transferred from donor to recipient cells. Because all cells ...

    Authors: Diogo Fortunato, Stavros Giannoukakos, Ana Giménez-Capitán, Michael Hackenberg, Miguel A. Molina-Vila and Nataša Zarovni
    Citation: Biomarker Research 2022 10:57
  5. Prostate cancer (PC) is a common tumor in men, and the incidence rate is high worldwide. Exosomes are nanosized vesicles released by all types of cells into multiple biological fluid types. These vesicles cont...

    Authors: Xiaolin Cui, Qiang Fu, Xueying Wang, Pengcheng Xia, Xianglun Cui, Xiaohui Bai and Zhiming Lu
    Citation: Biomarker Research 2022 10:56
  6. Circulating tumour DNA (ctDNA)-based sequencing might provide a simple test for the stratified model of non-small cell lung cancer (NSCLC). Here, we aimed to assess the ctDNA sequencing-based tumour mutation i...

    Authors: Jun Lu, Jun Wu, Yuqing Lou, Qin Shi, Jun Xu, Lele Zhang, Wei Nie, Jie Qian, Yanan Wang, Yanwei Zhang, Jing Jiao, Xueyan Zhang, Wei Zhang, Huimin Wang, Tianqing Chu, Hua Zhong…
    Citation: Biomarker Research 2022 10:55
  7. In our previous study, we found that lncRNA TRAF3IP2 antisense RNA 1 (TRAF3IP2-AS1) could play a critical role in the progression of NONO-TFE3 translocation renal cell carcinoma (NONO-TFE3 tRCC). However, the fun...

    Authors: Lei Yang, Yi Chen, Ning Liu, Yanwen Lu, Xin Li, Wenliang Ma, Weidong Gan and Dongmei Li
    Citation: Biomarker Research 2022 10:54
  8. Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumours of the head and neck in Southeast Asia and southern China. The Phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target o...

    Authors: Hai-Long LI, Nian-Hua Deng, Xiu-Sheng He and Yue-Hua Li
    Citation: Biomarker Research 2022 10:52
  9. Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma with variable clinical outcomes and prediction of prognosis remains important for long-term remission. We performed serial serum soluble interleu...

    Authors: Yu-Jia Huo, Peng-Peng Xu, Li Wang, Hui-Juan Zhong, Di Fu, Qing Shi, Shu Cheng, Shuo Wang, Mu-Chen Zhang and Wei-Li Zhao
    Citation: Biomarker Research 2022 10:51
  10. As one of the leading causes of death, hematologic malignancies are associated with an ever-increasing incidence, and drug resistance and relapse of patients after treatment represent clinical challenges. Ther...

    Authors: Fahua Deng, Chengsi Zhang, Tingting Lu, Ezhong Joshua Liao, Hai Huang and Sixi Wei
    Citation: Biomarker Research 2022 10:50
  11. Immunotherapy has become the major treatment for tumors in clinical practice, but some intractable problems such as the low response rate and high rates of immune-related adverse events still hinder the progre...

    Authors: Xi-Yang Tang, Yan-Lu Xiong, Xian-Gui Shi, Ya-Bo Zhao, An-Ping Shi, Kai-Fu Zheng, Yu-Jian Liu, Tao Jiang, Nan Ma and Jin-Bo Zhao
    Citation: Biomarker Research 2022 10:49
  12. Docetaxel (DTX) is the most widely prescribed first-line chemotherapy for advanced prostate cancer (PCa). Unfortunately, DTX resistance invariably emerges, leading to worse prognosis of PCa. Growing evidence h...

    Authors: Haoli Yin, Haixiang Qin, Lei Yang, Mengxia Chen, Yang Yang, Wenlong Zhang, Jiange Hao, Qun Lu, Jingyan Shi, Junlong Zhuang, Xuefeng Qiu and Hongqian Guo
    Citation: Biomarker Research 2022 10:48
  13. Immunotherapy using programmed cell death 1 (PD1) inhibitors has shown great efficacy in colorectal cancer patients harboring mismatch-repair-deficient (dMMR) and microsatellite instability-high (MSI-H) altera...

    Authors: Hui Meng, Wu Yao, Yuhui Yin, Yizhen Li, Yi Ding, Liang Wang and Mingzhi Zhang
    Citation: Biomarker Research 2022 10:47
  14. T-cell lymphoma (TCL) is an aggressive and genetically heterogeneous malignancy with adverse clinical outcomes; thus, it is worth exploring biomarkers for risk stratification. Previous studies have demonstrate...

    Authors: Cunte Chen, Shaohua Chen, Gengxin Luo, Liang Wang, Chengwu Zeng, Grzegorz K. Przybylski and Yangqiu Li
    Citation: Biomarker Research 2022 10:46
  15. Pediatric low-grade gliomas (pLGGs), particularly incompletely resected supratentorial tumours, can undergo progression after surgery. However to date, there are no predictive biomarkers for progression. Here,...

    Authors: Giuseppina Catanzaro, Zein Mersini Besharat, Andrea Carai, Natalie Jäger, Elena Splendiani, Carole Colin, Agnese Po, Martina Chiacchiarini, Anna Citarella, Francesca Gianno, Antonella Cacchione, Evelina Miele, Francesca Diomedi Camassei, Marco Gessi, Luca Massimi, Franco Locatelli…
    Citation: Biomarker Research 2022 10:44
  16. Immunotherapy of acute myeloid leukemia has experienced considerable advances, however novel target antigens continue to be sought after. To this end, unbiased approaches for surface protein detection are lim...

    Authors: Thomas Köhnke, Xilong Liu, Sascha Haubner, Veit Bücklein, Gerulf Hänel, Christina Krupka, Victor Solis-Mezarino, Franz Herzog and Marion Subklewe
    Citation: Biomarker Research 2022 10:43
  17. YAP1 (Yes-associated protein 1) is one of the principal factors that mediates oncogenesis by acting as a driver of gene expression. It has been confirmed to play an important role in organ volume control, stem...

    Authors: Haofeng Wu, Yachong Liu, Zhibin Liao, Jie Mo, Qiaofeng Zhang, Bixiang Zhang and Lei Zhang
    Citation: Biomarker Research 2022 10:42
  18. Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive gastrointestinal cancers with high incidence and mortality. Therefore, it is necessary to identify novel sensitive and specific biomarker...

    Authors: Chenxi Ju, Jing He, Chang Wang, Jinxiu Sheng, Jinlin Jia, Dan Du, Hongle Li, Mingxia Zhou and Fucheng He
    Citation: Biomarker Research 2022 10:41
  19. Thyroid cancer (TC) is one of the most frequent endocrine malignancies that is more common among females. Tumor recurrence is one of the most important clinical manifestations in differentiated TC which is ass...

    Authors: Amir Abbas Hamidi, Negin Taghehchian, Zahra Basirat, Amir Sadra Zangouei and Meysam Moghbeli
    Citation: Biomarker Research 2022 10:40
  20. Given the observed antitumor activity of immune-checkpoint-inhibitors in patients with mismatch-repair deficient (MSI-H) tumors, we hypothesized that deficiency in homologous-recombination-repair (HRR) can als...

    Authors: Miguel A. Villalona-Calero, John P. Diaz, Wenrui Duan, Zuanel Diaz, Eric D. Schroeder, Santiago Aparo, Troy Gatcliffe, Federico Albrecht, Siddhartha Venkatappa, Victor Guardiola, Sara Garrido, Muni Rubens, Fernando DeZarraga and Hao Vuong
    Citation: Biomarker Research 2022 10:39
  21. The claudin18.2 (CLDN18.2) protein, an isoform of claudin18, a member of the tight junction protein family, is a highly selective biomarker with limited expression in normal tissues and often abnormal expressi...

    Authors: Weijie Cao, Haizhou Xing, Yingmei Li, Wenliang Tian, Yongping Song, Zhongxing Jiang and Jifeng Yu
    Citation: Biomarker Research 2022 10:38
  22. Non-alcoholic fatty liver disease (NAFLD) is the commonest cause of chronic liver disease worldwide, being non-alcoholic steatohepatitis (NASH) its most clinically relevant form. Given the risks associated wit...

    Authors: Patricia Marañón, Carlos Ernesto Fernández-García, Stephania C. Isaza, Esther Rey, Rocío Gallego-Durán, Rocío Montero-Vallejo, Javier Rodríguez de Cía, Javier Ampuero, Manuel Romero-Gómez, Carmelo García-Monzón and Águeda González-Rodríguez
    Citation: Biomarker Research 2022 10:35
  23. In the last few decades, YAP has been shown to be critical in regulating tumor progression. YAP activity can be regulated by many kinase cascade pathways and proteins through phosphorylation and promotion of c...

    Authors: Yifan Cheng, Misha Mao and Yong Lu
    Citation: Biomarker Research 2022 10:34
  24. Immune checkpoint inhibitors have revolutionized cancer therapeutic paradigm and substantially improved the survival of patients with advanced malignancies. However, a significant limitation is the wide variab...

    Authors: Kamya Sankar, Jing Christine Ye, Zihai Li, Lei Zheng, Wenru Song and Siwen Hu-Lieskovan
    Citation: Biomarker Research 2022 10:32
  25. Exosomes, ranging in size from 30 to 150 nm as identified initially via electron microscopy in 1946, are one of the extracellular vesicles (EVs) produced by many cells and have been the subject of many studies...

    Authors: Ali Hazrati, Sara Soudi, Kosar Malekpour, Mohammad Mahmoudi, Arezou Rahimi, Seyed Mahmoud Hashemi and Rajender S. Varma
    Citation: Biomarker Research 2022 10:30
  26. Sestrin2 is a conserved antioxidant, metabolism regulator, and downstream of P53. Sestrin2 can suppress oxidative stress and inflammation, thereby preventing the development and progression of cancer. However,...

    Authors: Moein Ala
    Citation: Biomarker Research 2022 10:29
  27. Circular RNAs (circRNAs) are a type of recently discovered noncoding RNA. They exert their biological functions by competitively binding to microRNAs (miRNAs) as miRNA sponges, promoting gene transcription and...

    Authors: Qinfeng Zhou, Dacheng Xie, Rong Wang, Lianfang Liu, Yue Yu, Xinyi Tang, Yongxian Hu and Dawei Cui
    Citation: Biomarker Research 2022 10:28
  28. PD-L1 expression in non-small cell lung cancer (NSCLC) predicts response to immune checkpoint blockade, however is an imperfect biomarker given tumor heterogeneity, and the antigen presentation pathway requiri...

    Authors: Jennifer L. Schehr, Nan Sethakorn, Zachery D. Schultz, Camila I. Hernandez, Rory M. Bade, Diego Eyzaguirre, Anupama Singh, David J. Niles, Leslie Henderson, Jay W. Warrick, Scott M. Berry, Kaitlin E. Sundling, David J. Beebe, Ticiana A. Leal and Joshua M. Lang
    Citation: Biomarker Research 2022 10:26
  29. Kinase suppressor of Ras 2 (KSR2) is a regulator of MAPK signaling that is overactivated in most hepatocellular carcinoma (HCC). We sought to determine the role of KSR2 in HCC pathogenesis.

    Authors: Chao Gao, Si-wei Wang, Jia-cheng Lu, Xiao-qiang Chai, Yuan-cheng Li, Peng-fei Zhang, Xiao-yong Huang, Jia-bin Cai, Yi-min Zheng, Xiao-jun Guo, Guo-ming Shi, Ai-wu Ke and Jia Fan
    Citation: Biomarker Research 2022 10:25
  30. Chimeric antigen receptor T-cell (CAR-T) therapy is the result of combining genetic engineering-based cancer immunotherapy with adoptive cell therapy (ACT). CAR-T therapy has been successful in treating variou...

    Authors: Pouya Safarzadeh Kozani, Abdolhossein Naseri, Seyed Mohamad Javad Mirarefin, Faeze Salem, Mojtaba Nikbakht, Sahar Evazi Bakhshi and Pooria Safarzadeh Kozani
    Citation: Biomarker Research 2022 10:24
  31. Anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunotherapy has dramatically changed the therapeutic landscape of inoperable non-small cell lung cancer (NSCLC), and has been included in firs...

    Authors: Lin Zhang, Weihao Lin, Fengwei Tan, Ning Li, Qi Xue, Shugeng Gao, Yibo Gao and Jie He
    Citation: Biomarker Research 2022 10:23
  32. Platinum-based chemotherapy was previously the first-choice treatment for lung cancer. The discovery of epidermal growth factor receptor (EGFR) gene mutations and the development of EGFR tyrosine kinase inhibi...

    Authors: Jiabao Hou, Hongle Li, Shuxiang Ma, Zhen He, Sen Yang, Lidan Hao, Hanqiong Zhou, Zhe Zhang, Jing Han, Li Wang and Qiming Wang
    Citation: Biomarker Research 2022 10:21
  33. Heterogeneous nuclear ribonucleoproteins C (HnRNP C) is part of the hnRNP family of RNA-binding proteins. The relationship between hnRNP C and cancers has been extensively studied, and dysregulation of hnRNP C...

    Authors: Liyi Mo, Lijuan Meng, Zhicheng Huang, Lan Yi, Nanyang Yang and Guoqing Li
    Citation: Biomarker Research 2022 10:19
  34. Neuroblastoma (NB) is a malignant tumor in young children that originates from the neural crest of the sympathetic nervous system. Generally, NB occurs in the adrenal glands, but it can also affect the nerve t...

    Authors: Shaohui Huang, Naying Gong, Jiangbin Li, Mingye Hong, Li Li, Ling Zhang and Hua Zhang
    Citation: Biomarker Research 2022 10:18
  35. Acute myeloid leukemia (AML) has the lowest survival rate among the leukemias. Targeting intracellular metabolism and energy production in leukemic cells can be a promising therapeutic strategy for AML. Recent...

    Authors: Yi Xu, Christopher Hino, David J. Baylink, Jeffrey Xiao, Mark E. Reeves, Jiang F. Zhong, Saied Mirshahidi and Huynh Cao
    Citation: Biomarker Research 2022 10:16

    The Correction to this article has been published in Biomarker Research 2022 10:33

  36. Epigenetics including DNA and RNA modifications have always been the hotspot field of life sciences in the post-genome era. Since the first mapping of N6-methyladenosine (m6A) and the discovery of its widespread ...

    Authors: Hang Song, Jianye Zhang, Bin Liu, Jing Xu, Biao Cai, Hai Yang, Julia Straube, Xiyong Yu and Teng Ma
    Citation: Biomarker Research 2022 10:15
  37. Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of ...

    Authors: Tiffany C. Y. Tang, Ning Xu, Robert Nordon, Michelle Haber, Kenneth Micklethwaite and Alla Dolnikov
    Citation: Biomarker Research 2022 10:14
  38. Adoptive cell therapy (ACT) is a particularly promising area of cancer immunotherapy, engineered T and NK cells that express chimeric antigen receptors (CAR) are being explored for treating hematopoietic malig...

    Authors: Zhiwu Jiang, Le Qin, Yuou Tang, Rui Liao, Jingxuan Shi, Bingjia He, Shanglin Li, Diwei Zheng, Yuanbin Cui, Qiting Wu, Youguo Long, Yao Yao, Zhihui Wei, Qilan Hong, Yi Wu, Yuanbang Mai…
    Citation: Biomarker Research 2022 10:13
  39. Natural killer (NK) cells are unique innate immune cells and manifest rapid and potent cytotoxicity for cancer immunotherapy and pathogen removal without the requirement of prior sensitization or recognition o...

    Authors: Leisheng Zhang, Yuan Meng, Xiaoming Feng and Zhongchao Han
    Citation: Biomarker Research 2022 10:12

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 9.5
    5-year Journal Impact Factor: 9.4
    Source Normalized Impact per Paper (SNIP): 1.953
    SCImago Journal Rank (SJR): 3.024

    Speed 2023
    Submission to first editorial decision (median days): 5
    Submission to acceptance (median days): 72

    Usage 2023
    Downloads: 1,041,489
    Altmetric mentions: 353